Artículos científicos Open Access
Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic?
The Lancet Rheumatology
Su-Ann Yeoh, Michael R Ehrenstein
Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective
The Lancet Gastroenterology & Hepatology
Aisling Barry, Smith Apisarnthanarax, Grainne M O'Kane, Gonzalo Sapisochin, Robert Beecroft, Riad Salem, and others
Indigenous populations: left behind in the COVID-19 response
The Lancet
Kaitlin Curtice, Esther Choo
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
Leukemia
La Rosée, F., Bremer, H.C., Gehrke, I. et al.
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Nature
Williamson, B.N., Feldmann, F., Schwarz, B. et al
After COVID-19, green investment must deliver jobs to get political traction
Nature
Ryan Hanna, Yangyang Xu & David G. Victor
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
Scientific Reports
Jácome, R., Campillo-Balderas, J.A., Ponce de León, S. et al
A single-cell atlas of the peripheral immune response in patients with severe COVID-19
Nature Medicine
Wilk, A.J., Rustagi, A., Zhao, N.Q. et al
COVID-19 infection: the China and Italy perspectives
Cell Death & Disease
Chen, J., Lu, H., Melino, G. et al.
The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia
Cell Death & Disease
Shi, H., Wang, W., Yin, J. et al.
